Everyone with #EarlyOnsetCRC wants to know why they were diagnosed with #colorectalcancer.. This month's #CRCTrialsChat #VideoShorts on the @CancerGrand #PROSPECT project explores this question Let's hear from the PIs, Dr. @AndyChanMD & Dr. @yincaoScD! See you tomorrow! #CRCSM

An aspirin a day keeps the medical oncologist away? ALASCCA made waves at GI ASCO 🌊 when it showed that a cheap, widely available drug—low-dose aspirin—can meaningfully reduce recurrence risk in a genomically selected subset of colorectal cancer. This randomized,

Vitamin B12 for prophylaxis of capecitabine-associated hand–foot syndrome 💥Oral methylcobalamin reduced capecitabine-related HFS in HER2-negative early BC, with no added safety concerns 💬A simple prophylaxis option to support treatment adherence https://t.co/khCOH0RDv7

Find out more about our #LARS work at: https://t.co/0ZtwIcAR76 Together We Can Impact LARS!

#ScienceSaturday ❓ Why do some patients respond better to immunotherapy? ➡️ A new study in Nature found that tumors with mutations in PPP2R1A — a gene encoding a scaffold protein in the PP2A complex — were linked to much longer survival after immune checkpoint blockade (ICB).

If you live in SLC my daughter Emma has an art display all this month at the Hive Market in Trolley Square :) https://t.co/FuFMKgiP2B

💊 Oxaliplatin retreatment in refractory mCRC 🔗 https://t.co/ofJq6MLW5F 👥 102 pts (VH 3L/4L) 📊 PFS 4.0 mo | ORR 12% | DCR 39% ⭐ 27% best-responders ✅ Favorable: prior response, planned stop, ≥22 mo ox-free interval 🧬 No genomic predictors

I’ve been thinking a lot about how social media and AI are shaping conversations in oncology. Both create opportunities, but also bring bias and challenges we can’t ignore. #Oncology #CancerResearch #OncologyCommunity #ArtificialIntelligence #Transparency #BiasInAI #SocialMedia

Exciting science and clinical efficacy in this @MDAndersonNews team science study led by @VanMorrisMD In Cancer Cell. Triple therapy with IO led to durable responses in BRAF V600E MSS colorectal cancer, showing promise. Randomized study ongoing. #crcsm https://t.co/yg5gyQRqNK

Despite its rising incidence 📈 and poor outcomes, we still have a limited understanding of the biology driving early-onset colorectal cancer (<50y). Most prior studies were small, inconsistent, or confounded by MSI and treatment exposure. In JCO OA, Futreal, @skopetz , and

Excited and grateful for this opportunity! The study will open later this year and evaluate trifluridine/tipiracil plus oxaliplatin in advanced/metastatic biliary tract cancer as 2nd line therapy. #CancerResearch

👇❤️this! 🙏@DGlaucomflecken for highlighting @CDNCancerTrials 🇨🇦 #CHALLENGE trial @NEJM ✅ Exercise Saves Lives After Colon Cancer🚶

Dynamic evRNA changes linked E+C+N response to ⬆️ IFNg signatures in paired blood samples (🙏Kyuson Yun & team) Serial plasma collection on future trials for evRNA analyses is feasible, increases sample size, & improves translational interpretations = better pt care.

Pts w/BRAF V600E CRC need better therapies - targeting the immune activation signature for this CRC subpopulation is critical. Grateful to be on a highly collaborative + passionate + fun CRC team at @MDAndersonNews alongside the incredible @skopetz to #endcancer for #crcsm pts

Addition of PD1 blockade to BRAF+EGFR inhibition with E+C+N offers clear, extended benefit for pts with MSS, BRAF V600E mCRC. The follow-up @SWOG S2107 study comparing E+C w/ or w/o N in this same population has completed enrollment - results awaited.

Durable response > 2 years in MULTIPLE pts treated with E+C+N, and triple combo was well tolerated for this 2nd/3rd line MSS BRAF V600E population. Prior precedent w/ E+C (no nivo) in this setting showed ORR 20% and mPFS ~4 mos.👏👏👏 to @ParseghianC for writing this protocol

Clinical utility of liquid biopsy beyond ctDNA was shown! 🙏to @Aiims1742 & team, we saw concordance in baseline RNA signatures from tumor tissue AND plasma evRNA alike in association w/ treatment response: Resp- ⬆️ immune activation signatures Non-resp- ⬆️ metabolism signatures

VERY proud of our @MDAndersonNews team's work now online @Cancer_Cell for BRAF+EGFR+PD1 blockade in MSS, BRAF V600E mCRC. ORR 50%, mPFS >7 mos w/encorafenib + cetuximab + nivolumab 🧵to expand IO benefit+liquid biopsy utility in high-risk MSS CRC pts https://t.co/PvL2SdFG3g

It seems odd that a 100 person study without controls merits the front page of the NY Times. Many recent reports indicate a rising incidence of colon cancer (and expected pre-cancerous polyps) among the young (participants in this study were age 35-50) https://t.co/0Nl4ICvQvr

@PSOGI_EC @PSugarbaker @indepso @SPeritoneum @NewsJellybelly @PMPSurvivor @DrFloresAyala @drmaikelp @Dr_Jamie_Murphy @CrcTrialsChat @alarjosan @Ajthrower_ @FaheezM Interesting case! We would have done upfront maximum CRS/HIPEC and reach CC1. We tend to spare the small bowel as much as possible preferring to mechanically wipe the aerosol surfaces. Amazingly, recurrences are relatively few despite this CC-1.

@PSOGI_EC @indepso @SPeritoneum @NewsJellybelly @PMPSurvivor @DrFloresAyala @drmaikelp @Dr_Jamie_Murphy @CrcTrialsChat @alarjosan @Ajthrower_ @FaheezM The imaging, especially the MRI, suggests to me a robust response to the neoadjuvant chemo. The subdiaphragmatic disease is markedly reduced. The pelvic masses are much less prominent.